BioCentury
ARTICLE | Regulation

WHO counters FDA as it recommends against Veklury for COVID-19

November 20, 2020 12:28 AM UTC

The WHO’s new guidance counters FDA’s October approval of Gilead’s Veklury for hospitalized patients, adding to the debate around the drug’s use and variable performance in randomized, controlled trials.

In The BMJ on Thursday, the WHO issued a “weak or conditional recommendation against” treating hospitalized COVID-19 patients with Veklury remdesivir from  Gilead Sciences Inc. (NASDAQ:GILD)...